Phenex Pharmaceuticals

Phenex specializes in the discovery of small-molecule drugs targeting nuclear receptors, with a primary focus on liver diseases, cancer, and autoimmune or chronic inflammatory disorders. The company's business model revolves around identifying and advancing proprietary drug candidates through the preclinical and early clinical stages before forming strategic partnerships with larger pharmaceutical companies for late-stage development and commercialization. This strategy is exemplified by two major agreements. In December 2012, Phenex licensed its RORγt program for chronic inflammatory and autoimmune diseases to Janssen Biotech. A more significant milestone occurred in 2014 when its Farnesoid X Receptor (FXR) program, including the lead drug candidate Cilofexor (formerly GS-9674) for non-alcoholic steatohepatitis (NASH), was acquired by Gilead Sciences. The deal with Gilead included an upfront payment and potential milestone payments of up to $470 million.

The company's core competency lies in its deep expertise in targeting nuclear receptors, which are crucial regulators of metabolism and inflammation. Its pipeline has included drug candidates like PX-102 for metabolic syndrome and NASH, as well as inverse agonists for the ROR-gamma receptor to treat autoimmune conditions such as rheumatoid arthritis and psoriasis. By focusing on the research and discovery phases, Phenex generates revenue through licensing fees, milestone payments, and outright program acquisitions from its partners, which include major players in the pharmaceutical industry. The company has successfully raised capital to fund its research, securing $24.5 million over three funding rounds, with the latest being a Series C round in 2010.